Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to $5.8 million.

  • Integra Lifesciences Holdings' Change in Accured Expenses fell 1529.45% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 13601.57%. This contributed to the annual value of -$2.7 million for FY2024, which is 8678.14% up from last year.
  • Per Integra Lifesciences Holdings' latest filing, its Change in Accured Expenses stood at $5.8 million for Q3 2025, which was down 1529.45% from $15.9 million recorded in Q2 2025.
  • Over the past 5 years, Integra Lifesciences Holdings' Change in Accured Expenses peaked at $18.1 million during Q4 2022, and registered a low of -$19.2 million during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is $1.6 million, with a median of $1.9 million in 2023.
  • Per our database at Business Quant, Integra Lifesciences Holdings' Change in Accured Expenses surged by 194410.57% in 2022 and then crashed by 38033.47% in 2024.
  • Quarter analysis of 5 years shows Integra Lifesciences Holdings' Change in Accured Expenses stood at -$984000.0 in 2021, then soared by 1944.11% to $18.1 million in 2022, then plummeted by 89.46% to $1.9 million in 2023, then crashed by 380.33% to -$5.4 million in 2024, then soared by 207.87% to $5.8 million in 2025.
  • Its Change in Accured Expenses stands at $5.8 million for Q3 2025, versus $15.9 million for Q2 2025 and -$18.0 million for Q1 2025.